Cost-effectiveness of bariatric and metabolic surgery, and implications of COVID-19 in the United Kingdom.

ABSTRACT: People living with obesity have been among those most disproportionately impacted by the COVID-19 pandemic, highlighting the urgent need for increased provision of bariatric and metabolic surgery (BMS). To evaluate the possible clinical and economic benefits of BMS compared with nonsurgical treatment options in the UK, considering the broader impact that COVID-19 has on people living with obesity. Single-payer healthcare system (National Health Service, England). A Markov model compared lifetime costs and outcomes of BMS and conventional treatment among patients with body mass index (BMI) ≥ 40 kg/m2, BMI ≥ 35 kg/m2 with obesity-related co-morbidities (Group A), or BMI ≥ 35 kg/m2 with type 2 diabetes (T2D; Group B). Inputs were sourced from clinical audit data and literature sources; direct

SUBMITTER: Galvain T 

PROVIDER: S-EPMC8313820 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature